All In Biotech

NDA 018829 · Chartwell Molecules

Indomethacin

Indomethacin · Oral · Nonsteroidal Anti-inflammatory Drug

Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Aug 6, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

557

100 Phase 3, 44 recruiting

FAERS reports

11,101

9,017 serious, 1,293 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see WARNINGS ). Indomethacin is contraindicated in the setting of coronary artery bypass graft (CABG) surgery ( see CONTRAINDICATIONS and WARNINGS ). Gastrointestinal Risk NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. ( See WARNINGS ).

What it is approved for

From the label in effect Mar 26, 2025.

INDICATIONS AND USAGE Carefully consider the potential benefits and risks of indomethacin capsules, USP and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals ( see Warnings: Gastrointestinal Bleeding, Ulceration, and Perforation ). Indomethacin has been found effective in active stages of the following: 1. Moderate to severe rheumatoid arthritis including acute flares of chronic disease. 2. Moderate to severe ankylosing spondylitis. 3. Moderate to severe osteoarthritis. 4. Acute painful shoulder (bursitis and/or tendinitis). 5. Acute gouty arthritis.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 6, 1984 Original approval
2 products under this application
  • INDOMETHACIN · INDOMETHACIN 25MG · CAPSULE, ORAL · Prescription · TE AB
  • INDOMETHACIN · INDOMETHACIN 50MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Indomethacin" as an intervention, any sponsor and status, largest first.

All 557 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,316
  • fatigue1,063
  • headache978
  • off label use968
  • arthralgia957
  • pain851
  • nausea840
  • diarrhoea837
  • dizziness805
  • vomiting689
  • dyspnoea681
  • asthenia599

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004218
2005264
2006278
2007257
2008266
2009307
2010270
2011371
2012458
2013314
2014280
2015385
2016540
2017466
2018649
2019707
2020583
2021716
2022981
2023843
2024873
2025732
2026342

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Indomethacin* (Indomethacin)

2024 spending

$3.6M

Beneficiaries

124,276

247,264 claims

Per beneficiary

$29

$0.26 per unit

View as table
YearSpending
2020$3,836,873
2021$3,515,006
2022$3,425,921
2023$3,235,993
2024$3,559,363

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,045 on PubMed

Sponsor: Chartwell Molecules

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.